Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

447 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Keystone E, Heijde Dv, Mason D Jr, Landewé R, Vollenhoven RV, Combe B, Emery P, Strand V, Mease P, Desai C, Pavelka K. Keystone E, et al. Arthritis Rheum. 2008 Nov;58(11):3319-29. doi: 10.1002/art.23964. Arthritis Rheum. 2008. PMID: 18975346 Free article. Clinical Trial.
Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis.
Keystone E, Fleischmann R, Emery P, Furst DE, van Vollenhoven R, Bathon J, Dougados M, Baldassare A, Ferraccioli G, Chubick A, Udell J, Cravets MW, Agarwal S, Cooper S, Magrini F. Keystone E, et al. Arthritis Rheum. 2007 Dec;56(12):3896-908. doi: 10.1002/art.23059. Arthritis Rheum. 2007. PMID: 18050221 Free article. Clinical Trial.
Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension.
Keystone E, Landewé R, van Vollenhoven R, Combe B, Strand V, Mease P, Shaughnessy L, VanLunen B, van der Heijde D. Keystone E, et al. Ann Rheum Dis. 2014 Dec;73(12):2094-100. doi: 10.1136/annrheumdis-2013-203695. Epub 2013 Aug 5. Ann Rheum Dis. 2014. PMID: 23918037 Free PMC article. Clinical Trial.
Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial.
Smolen JS, Van Der Heijde DM, St Clair EW, Emery P, Bathon JM, Keystone E, Maini RN, Kalden JR, Schiff M, Baker D, Han C, Han J, Bala M; Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) Study Group. Smolen JS, et al. Among authors: keystone e. Arthritis Rheum. 2006 Mar;54(3):702-10. doi: 10.1002/art.21678. Arthritis Rheum. 2006. PMID: 16508926 Free article. Clinical Trial.
American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials.
Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, Aletaha D, Allaart CF, Bathon J, Bombardieri S, Brooks P, Brown A, Matucci-Cerinic M, Choi H, Combe B, de Wit M, Dougados M, Emery P, Furst D, Gomez-Reino J, Hawker G, Keystone E, Khanna D, Kirwan J, Kvien TK, Landewé R, Listing J, Michaud K, Martin-Mola E, Montie P, Pincus T, Richards P, Siegel JN, Simon LS, Sokka T, Strand V, Tugwell P, Tyndall A, van der Heijde D, Verstappen S, White B, Wolfe F, Zink A, Boers M; American College of Rheumatology; European League Against Rheumatism. Felson DT, et al. Among authors: keystone e. Arthritis Rheum. 2011 Mar;63(3):573-86. doi: 10.1002/art.30129. Arthritis Rheum. 2011. PMID: 21294106 Free PMC article.
Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study.
van der Heijde D, Strand V, Tanaka Y, Keystone E, Kremer J, Zerbini CAF, Cardiel MH, Cohen S, Nash P, Song YW, Tegzová D, Gruben D, Wallenstein G, Connell CA, Fleischmann R; ORAL Scan Investigators. van der Heijde D, et al. Among authors: keystone e. Arthritis Rheumatol. 2019 Jun;71(6):878-891. doi: 10.1002/art.40803. Epub 2019 Apr 24. Arthritis Rheumatol. 2019. PMID: 30666826 Free PMC article. Clinical Trial.
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial.
St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, Keystone E, Schiff M, Kalden JR, Wang B, Dewoody K, Weiss R, Baker D; Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group. St Clair EW, et al. Among authors: keystone e. Arthritis Rheum. 2004 Nov;50(11):3432-43. doi: 10.1002/art.20568. Arthritis Rheum. 2004. PMID: 15529377 Free article. Clinical Trial.
Efficacy and safety of tregalizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase IIb, randomised, placebo-controlled trial.
van Vollenhoven RF, Keystone EC, Strand V, Pacheco-Tena C, Vencovský J, Behrens F, Racewicz A, Zipp D, Rharbaoui F, Wolter R, Knierim L, Schmeidl R, Zhou X, Aigner S, Dälken B, Wartenberg-Demand A; TREAT2b study team. van Vollenhoven RF, et al. Ann Rheum Dis. 2018 Apr;77(4):495-499. doi: 10.1136/annrheumdis-2017-212478. Epub 2018 Jan 17. Ann Rheum Dis. 2018. PMID: 29343509 Clinical Trial.
447 results